Molecular Monitoring of Minimal Residual Disease in Patients with Multiple Myeloma

References

• Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. and Bataille, R. (1996) "A prospective, randomized trial of autologous bone marrow transplanta-tion and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome", N. Engl. J. Med. 335, 91–97.
   PubMed Web of Science ®Google Scholar
• Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. and Selby, P.J. (2003) "High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma", N. Engl. J. Med. 348, 1875–1883.
   PubMed Web of Science ®Google Scholar
• Vesole, D.H., Barlogie, B., Jagannath, S., Cheson, B., Tricot, G., Alexanian, R. and Crowley, J. (1994) "High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants", Blood 84, 950–956.
   PubMed Web of Science ®Google Scholar
• Segeren, C.M., Sonneveld, P., Van Der, H.B., Vellenga, E., Croockewit, A.J., Verhoef, G.E., Cornelissen, J.J., Schaafsma, M.R., van Oers, M.H., Wijermans, P.W., Fibbe, W.E., Wittebol, S., Schouten, H.C., van Marwijk, K.M., Biesma, D.H., Baars, J.W., Slater, R., Steijaert, M.M., Buijt, I. and Lokhorst, H.M. (2003) "Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study", Blood 101, 2144–2151.
   PubMed Web of Science ®Google Scholar
• Attal, M. and Harousseau, J.L. (2001) "Randomized trial experience of the Intergroupe Francophone du Myelome", Semin. Hematol. 38, 226–230.
   PubMed Web of Science ®Google Scholar
• Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Bathos, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P. and Crowley, J. (2000) "Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remis-sions and superior survival in the absence of chromosome 13 abnormalities", Blood 95, 4008–4010.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. and Crowley, J. (1999) "Total therapy with tandem transplants for newly diagnosed multiple myeloma", Blood 93, 55–65.
   PubMed Web of Science ®Google Scholar
• Laterveer, L., Verdonck, L.F., Peeters, T., Borst, E., Bloem, A.C. and Lokhorst, H.M. (2003) "Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma", Blood 101, 1201–1202.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Vesole, D.H., Jagannath, S., Hilton, J., Munshi, N. and Barlogie, B. (1996) "Graft-versus-myeloma effect: proof of principle", Blood 87, 1196–1198.
   PubMed Web of Science ®Google Scholar
• Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., van Oers, M.H., Fibbe, W., Russell, I., Donk, N.W. and Verdonck, L.F. (2000) "Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome", J. Clin. Oncol. 18, 3031–3037.
   PubMed Web of Science ®Google Scholar
• Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., Thomas, L.L. and Verdonck L.F. (1997) "Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation", Blood 90, 4206–4211.
   PubMed Web of Science ®Google Scholar
• Alyea, E., Weller, E., Schlossman, R., Canning, C., Webb, I., Doss, D., Mauch, P., Marcus, K., Fisher, D., Freeman, A., Parikh, B., Gribben, J., Soiffer, R., Ritz, J. and Anderson, K. (2001) "T-cell-depleted allogeneic bone marrow transplanta-tion followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect", Blood 98, 934–939.
   PubMed Web of Science ®Google Scholar
• Le Blanc, R., Montminy-Metivier, S., Belanger, R., Busque, L., Fish, D., Roy, D.C., Kassis, J., Boileau, J., Lavallee, R., Belanger, D., Letendre, F., Hebert, J., Sauvageau, G., Perreault, C. and Roy, J. (2001) "Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect", Bone Marrow Transplant. 28, 841–848.
   PubMed Web of Science ®Google Scholar
• Gahrton, G., Svensson, H., Cavo, M., Apperly, J., Bacigalupo, A., Bjorkstrand, B., Blade, J., Cornelissen, J., de Laurenzi, A., Facon, T., Ljungman, P, Michallet, M., Niederwieser, D., Powles, R., Reiffers, J., Russell, N.H., Samson, D., Schaefer, U.W., Schattenberg, A., Tura, S., Verdonck L.F., Vernant, J.P., Willemze, R. and Volin, L. (2001) "Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres", Br. J. Haematol. 113, 209–216.
   PubMed Web of Science ®Google Scholar
• Bjorkstrand, B.B., Ljungman, P., Svensson, H., Hermans, J., Alegre, A., Apperley, J., Blade, J., Carlson, K., Cavo, M., Ferrant, A., Goldstone, A.H., de Laurenzi, A., Majolino, I., Marcus, R., Prentice, H.G., Remes, K., Samson, D., Sureda, A., Verdonck, L.F., Volin, L. and Gahrton, G. (1996) "Allogeneic bone marrow transplantation versus auto-logous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation", Blood 88, 4711–4718.
   PubMed Web of Science ®Google Scholar
• Gahrton, G., Tura, S., Ljungman, P., Belanger, C., Brandt, L., Cavo, M., Facon, T., Granena, A., Gore, M. and Gratwohl, A. (1991) "Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplanta-tion", N. Engl. J. Med. 325, 1267–1273.
   PubMed Web of Science ®Google Scholar
• Kroger, N., Einsele, H., Wolff, D., Casper, J., Freund, M., Derigs, G., Wandt, H., Schafer-Eckart, K., Wittkowsky, G., Schmitz, N., Kruger, W., Zabelina, T., Renges, H., Ayuk, F., Krull, A. and Zander, A. (2003) "Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)", Bone Marrow Transplant. 31, 973–979.
   PubMed Web of Science ®Google Scholar
• Lokhorst, H.M., Segeren, C.M., Verdonck, L.F., Van Der, H.B., Raymakers, R., van Oers, M.H., Barge, R.M., Schouten, H.C., Westveer, P.H., Steijaert, M.M., Cornelissen, J.J. and Sonneveld, P. (2003) "Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase DI study HOVON 24 MM", J. Clin. Oncol. 21, 1728–1733.
   PubMed Web of Science ®Google Scholar
• Lee, C.K., Badros, A., Barlogie, B., Morris, C., Zangari, M., Fassas, A., van Rhee, F., Cottler-Fox, M., Jacobson, J., Thertulien, R., Muwalla, F., Mazher, S., Anaissie, E. and Tricot, G. (2003) "Prognostic factors in allogeneic trans-plantation for patients with high-risk multiple myeloma after reduced intensity conditioning", Exp. Hematol. 31, 73–80.
   PubMed Web of Science ®Google Scholar
• Maloney, D.C., Molina, A.J., Sahebi, F., Stockerl-Goldstein, K.E., Sandmaier, B.M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., Bruno, B., Appelbaum, F.R., Blume, K.G., Forman, S.J., McSweeney, P. and Storb, R. (2003) "Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma", Blood 102, 3447–3454. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Kobbe, G., Schneider, P., Aivado, M., Zohren, E, Schubert, D., Fenk, R., Neumann, E, Kronenwett, R., Pape, H., Rong, A., Royer-Pokora, B., Hildebrandt, B., Germing, U., Gattermann, N., Hey11, A. and Haas, R. (2002) "Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning", Exp. Hematol. 30, 1346–1353.
   PubMed Web of Science ®Google Scholar
• Bathos, A., Barlogie, B., Siegel, E., Cottler-Fox, M., Zangari, M., Fassas, A., Morris, C., Anaissie, E., van Rhee, E and Tricot, G. (2002) "Improved outcome of allogeneic trans-plantation in high-risk multiple myeloma patients after nonmyeloablative conditioning", J. Clin. Oncol. 20, 1295–1303.
   PubMed Web of Science ®Google Scholar
• Kroger, N., Schwerdtfeger, R., Kiehl, M., Sayer, H.G., Renges, H., Zabelina, T., Fehse, B., Togel, E, Wittkowsky, G., Kuse, R. and Zander, A.R. (2002) "Autologous stem cell transplan-tation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma", Blood 100, 755–760.
   PubMed Web of Science ®Google Scholar
• Kroger, N., Sayer, H.G., Schwerdtfeger, R., Kiehl, M., Nagler, A., Renges, H., Zabelina, T., Fehse, B., Ayuk, E, Wittkowsky, G., Schmitz, N. and Zander, A.R. (2002) "Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality", Blood 100, 3919–3924.
   PubMed Web of Science ®Google Scholar
• Giralt, S., Aleman, A., Anagnostopoulos, A., Weber, D., Khouri, I., Anderlini, P., Molldrem, J., Ueno, N.T., Donato, M., Korbling, M., Gajewski, J., Alexanian, R. and Champlin, R. (2002) "Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma", Bone Marrow Transplant. 30, 367–373.
   PubMed Web of Science ®Google Scholar
• Willemse, M.J., Seriu, T., Hettinger, K., d'Aniello, E., Hop, W.C., Panzer-Grumayer, E.R, Biondi, A., Schrappe, M., Kamps, W.A., Masera, G., Gadner, H., Riehm, H., Bartram, C.R. and van Dongen, J.J. (2002) "Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL", Blood 99,4386–4393.
   PubMed Web of Science ®Google Scholar
• Hoelzer, D., Gokbuget, N., Ottmann, O., Pui, C.H., Relling, M.V., Appelbaum, F.R., van Dongen, J.J. and Szczepanski, T. (2002) "Acute lymphoblastic leukemia", Hematology, Am. Soc. Hematol. Educ. Program 162–192.
   Google Scholar
• Neumann, E, Herold, C., Hildebrandt, B., Kobbe, G., Aivado, M., Rong, A., Free, M., Rossig, R., Fenk, R., Schneider, P., Gattermann, N., Royer-Pokora, B., Haas, R. and Kronenwett, R. (2003) "Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation", Fur. J. Haematol. 70, 1–10.
   PubMed Web of Science ®Google Scholar
• Hochhaus, A. (2002) "Minimal residual disease in chronic myeloid leukaemia patients", Best Pract. Res. Clin. Haematol. 15, 159–178.
   PubMed Web of Science ®Google Scholar
• Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. and Vesole, D. (1998) "Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplanta-tion. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant", Br. J. Haematol. 102, 1115–1123.
   PubMed Web of Science ®Google Scholar
• Davies, EE., Forsyth, ED., Rawstron, A.C., Owen, R.G., Pratt, G., Evans, P.A., Richards, S.J., Drayson, M., Smith, G.M., Selby, P.J., Child, J.A. and Morgan, G.J. (2001) "The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma", Br. J. Haematol. 112, 814–819.
   PubMed Web of Science ®Google Scholar
• Alexanian, R., Weber, D., Giralt, S., Dimopoulos, M., Delasalle, K., Smith, T. and Champlin, R. (2001) "Impact of complete remission with intensive therapy in patients with responsive multiple myeloma", Bone Marrow Transplant. 27, 1037–1043.
   PubMed Web of Science ®Google Scholar
• Lahuerta, J.J., Martinez-Lopez, J., Serna, J.D., Blade, J., Grande, C., Alegre, A., Vazquez, L., Garcia-Larana, J., Sureda, A., Rubia, J.D., Conde, E., Martinez, R., Perez-Equiza, K., Moraleda, J.M., Leon, A., Besalduch, J., Cabrera, R., Miguel, J.D., Morales, A., Garcia-Ruiz, J.C., Diaz-Mediavilla, J. and San Miguel, J. (2000) "Remission status defined by immunofixation vs. electrophoresis after auto-logous transplantation has a major impact on the outcome of multiple myeloma patients", Br. J. Haematol. 109, 438–446.
   PubMed Web of Science ®Google Scholar
• Shaughnessy, J., Jr., Tian, E., Sawyer, J., McCoy, J., Tricot, G., Jacobson, J., Anaissie, E., Zangari, M., Fassas, A., Muwalla, E, Morris, C. and Barlogie, B. (2003) "Prognostic impact of cytogenetic and interphase fluorescence in situ hybridiza-tion-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II", Br. J. Haematol. 120, 44–52.
   PubMed Web of Science ®Google Scholar
• Fassas, A.B., Spencer, T., Sawyer, J., Zangari, M., Lee, C.K., Anaissie, E., Muwalla, F., Morris, C., Barlogie, B. and Tricot, G. (2002) "Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma", Br. J. Haematol. 118, 1041–1047.
   PubMed Web of Science ®Google Scholar
• Konigsberg, R., Zojer, N., Ackermarm, J., Kromer, E., Kittler, H., Fritz, E., Kaufmann, H., Nosslinger, T., Riedl, L., Gisslinger, H., Jager, U., Simonitsch, I., Heinz, R., Ludwig, H., Huber, H. and Drach, J. (2000) "Predictive role of interphase cytogenetics for survival of patients with multiple myeloma", J. Clin. Oncol. 18, 804–812.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S.V., Fonseca, R., Dewald, G.W., Therneau, TM., Lacy, M.Q., Kyle, R.A., Greipp, P.R. and Gertz, MA. (1999) "Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma", Cancer Genet. Cytogenet. 113, 73–77.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S., Fonseca, R., Lacy, M., Witzig, T., Lust, J., Greipp, P., Therneau, T., Kyle, R., Litzow, M. and Gertz, M. (1999) "Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma", Bone Marrow Transplant. 24, 497–503.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D.H., Naucke, S. and Sawyer, J.R. (1995) "Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities", Blood 86, 4250–4256.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Sawyer, J.R., Jagannath, S., Desikan, KR., Siegel, D., Naucke, S., Mattox, S., Bracy, D., Munshi, N. and Barlogie, B. (1997) "Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants", J. Clin. Oncol. 15, 2659–2666.
   PubMed Web of Science ®Google Scholar
• Davies, EE., Rawstron, A.C., Owen, R.G. and Morgan, G.J. (2002) "Minimal residual disease monitoring in multiple myeloma", Best. Pract. Res. Clin. Haematol. 15, 197–222.
   PubMed Web of Science ®Google Scholar
• Rawstron, A., Barrans, S., Blythe, D., Davies, E, English, A., Pratt, G., Child, A., Morgan, G. and Jack, A. (1999) "Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression", Br. J. Haematol. 104, 138–143.
   PubMed Web of Science ®Google Scholar
• Rawstron, A.C., Davies, EE., DasGupta, R., Ashcroft, A.J., Patmore, R., Drayson, MT., Owen, R.G., Jack, AS., Child, J.A. and Morgan, G.J. (2002) "Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation", Blood 100, 3095–3100.
   PubMed Web of Science ®Google Scholar
• Rawstron, A.C., Fenton, J.A., Ashcroft, J., English, A., Jones, R.A., Richards, S.J., Pratt, G., Owen, R., Davies, EE., Child, J.A., Jack, AS. and Morgan, G. (2000) "The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells", Blood 96, 3880–3886.
   PubMed Web of Science ®Google Scholar
• Rawstron, A.C., Owen, R.G., Davies, EE., Johnson, R.J., Jones, R.A., Richards, S.J., Evans, PA., Child, J.A., Smith, G.M., Jack, AS. and Morgan, G.J. (1997) "Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage", Br. J. Haematol. 97, 46–55.
   PubMed Web of Science ®Google Scholar
• Almeida, J., Orfao, A., Ocqueteau, M., Mateo, G., Corral, M., Caballero, M.D., Blade, J., Moro, M.J., Hernandez, J. and San Miguel, J.F. (1999) "High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma", Br. J. Haematol. 107, 121–131.
   PubMed Web of Science ®Google Scholar
• Escribano, L., Ocqueteau, M., Almeida, J., Orfao, A. and San Miguel, J.F. (1998) "Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis", Leuk. Lymphoma 30, 459–466.
   PubMed Web of Science ®Google Scholar
• Witzig, T.E., Meyers, C., Therneau, T. and Greipp, P.R. (2000) "A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders", Leuk. Lymphoma 38, 345–350.
   PubMed Web of Science ®Google Scholar
• Witzig, T.E., Kimlinger, T., Stenson, M. and Therneau, T. (1998) "Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia", Leuk. Lymphoma 31, 167–175.
   PubMed Web of Science ®Google Scholar
• Witzig, T.E., Gertz, M.A., Lust, J.A., Kyle, R.A., O'Fallon, W.M. and Greipp, P.R. (1996) "Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma", Blood 88, 1780–1787.
   PubMed Web of Science ®Google Scholar
• Galimberti, S., Morabito, E, Guerrini, E, Palumbo, G.A., Azzara, A., Martino, M., Benedetti, E., Di Raimondo, F. and Petrini, M. (2003) "Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients", Br. J. Haematol. 120, 405–412.
   PubMed Web of Science ®Google Scholar
• Galimberti, S., Brizzi, F., Mameli, M. and Petrini, M. (1999) "An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection", Leuk. Res. 23, 921–929.
   PubMed Web of Science ®Google Scholar
• Novella, E., Giaretta, I., Elice, E, Madeo, D., Piccin, A., Castaman, G. and Rodeghiero, F. (2002) "Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma", Haematologica 87, 1157–1164.
   PubMed Web of Science ®Google Scholar
• Gleissner, B., Maurer, J., Sindram, A., Reinhard, R. and Thiel, E. (2001) "Comparison of ethidium bromide-stained agarose gel electrophoresis and automated fragment analysis for evaluation of IgH gene products", Leuk. Res. 25, 769–774.
   PubMed Web of Science ®Google Scholar
• Welterlin, V, Debecker, A., Tschieb, D., Zanetti, C., Lange, W. and Henon, P.R. (2000) "Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers", J. Hematother. Stein Cell Res. 9, 983–991.
   PubMedGoogle Scholar
• Linke, B., Bolz, I., Fayyazi, A., von Hofen, M., Pott, C., Bertram, J., Hiddemann, W. and Kneba, M. (1997) "Auto-mated high resolution PCR fragment analysis for identifi-cation of clonally rearranged immunoglobulin heavy chain genes", Leukemia 11, 1055–1062.
   PubMed Web of Science ®Google Scholar
• Lopez-Perez, R., Garcia-Sanz, R., Gonzalez, D., Balanzategui, A., Chillon, MC., Alaejos, I., Mateos, UV, Caballero, M.D., Mateo, G., Nieto, M.J., Gonzalez, M. and San Miguel, J.F. (2000) "The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation", Leukemia 14, 1493–1499.
   PubMed Web of Science ®Google Scholar
• Tarin, F., Orero, M., Garcia, AM., Miguel-Sosa, A., Sanchez, M., Marco, J., Carbonell, F. and Linares, M. (1997) "Prognosis value of the monoclonal blood plasma cells in multiple myeloma", Blood 89, 3065–3066.
   PubMed Web of Science ®Google Scholar
• Mitterer, M., Lanthaler, A.J., Schnabel, B., Svaldi, M., Oduncu, E, Coser, P., Emmerich, B., Huemer, H. and Straka, C. (2001) "Peripheral blood monoclonal B-cells predict the event free survival in multiple myeloma", Leuk. Lymphoma 41, 387–395.
   PubMed Web of Science ®Google Scholar
• Voena, C., Ladetto, M., Astolfi, M., Provan, D., Gribben, J.G., Boccadoro, M., Pileri, A. and Corradini, P. (1997) "A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors", Leukemia 11, 1793–1798.
   PubMed Web of Science ®Google Scholar
• Togel, F., Kroger, N., Korioth, E, Fehse, B. and Zander, A.R. (2002) "Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR", J. Hematot her. Stem Cell Res. 11, 971–976.
   PubMed Web of Science ®Google Scholar
• Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Sahebi, E, Lee, M., Wu, C.H., Cao, J., Lee, J.C. and Hong, C.H. (1995) "Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma", Blood 86, 390–397.
   PubMed Web of Science ®Google Scholar
• Vescio, R.A., Han, E.J., Schiller, G.J., Lee, J.C., Wu, C.H., Cao, J., Shin, J., Kim, A., Lichtenstein, A.K. and Berenson, J.R. (1996) "Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts", Bone Marrow Transplant. 18, 103–110.
   PubMed Web of Science ®Google Scholar
• Cremer, F.W., Kiel, K., Wallmeier, M., Goldschmidt, H. and Moos, M. (1997) "A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma", Ann. Oncol. 8, 633–636.
   PubMed Web of Science ®Google Scholar
• Sykes, P.J., Neoh, S.H., Brisco, M.J., Hughes, E., Condon, J. and Morley, A.A. (1992) "Quantitation of targets for PCR by use of limiting dilution", Biotechniques 13, 444–449.
   PubMed Web of Science ®Google Scholar
• Gerard, C.J., Olsson, K., Ramanathan, R., Reading, C. and Hanania, E.G. (1998) "Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complemen-tarity determining region III standards", Cancer Res. 58, 3957–3964.
   PubMed Web of Science ®Google Scholar
• Ladetto, M., Donovan, J.W., Harig, S., Trojan, A., Poor, C., Schlossnan, R., Anderson, K.C. and Gribben, J.G. (2000) "Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma", Biol. Blood Marrow Transplant. 6, 241–253.
   PubMed Web of Science ®Google Scholar
• Willems, P., Verhagen, O., Segeren, C., Veenhuizen, P., Guikema, J., Wiemer, E., Groothuis, L., Jong, TB., Kok, H., Bloem, A., Bos, N., Vellenga, E., Mensink, E., Sonneveld, P., Lokhorst, H., van Der, S. and Raymakers, R. (2000) "Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium—Dutch Hematology—Oncology Group", Blood 96, 63–70.
   PubMed Web of Science ®Google Scholar
• Rasmussen, T., Poulsen, T.S., Honore, L. and Johnsen, H.E. (2000) "Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay", Exp. Hematol. 28, 1039–1045.
   PubMed Web of Science ®Google Scholar
• Bakkus, M.H., Heirman, C., Van, I, R., Van Camp, B. and Thielemans, K. (1992) "Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation", Blood 80, 2326–2335.
   PubMed Web of Science ®Google Scholar
• Vescio, R.A., Cao, J., Hong, C.H., Lee, J.C., Wu, C.H., Der, D.M., Wu, V, Newman, R., Lichtenstein, A.K. and Berenson, J.R. (1995) "Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity", J. Immunol. 155, 2487–2497.
   PubMed Web of Science ®Google Scholar
• Tonegawa, S. (1983) "Somatic generation of antibody diversity", Nature 302, 575–581.
   PubMed Web of Science ®Google Scholar
• Stewart, A.K. and Schwartz, R.S. (1994) "Immunoglobulin V regions and the B cell", Blood 83, 1717–1730.
   PubMed Web of Science ®Google Scholar
• Alt, F.W., Blackwell, T.K. and Yancopoulos, G.D. (1987) "Development of the primary antibody repertoire", Science 238, 1079–1087.
   PubMed Web of Science ®Google Scholar
• Sahota, S.S., Leo, R., Hamblin, T.J. and Stevenson, F.K. (1997) "Myeloma VL and VH gene sequences reveal a complemen-tary imprint of antigen selection in tumor cells", Blood 89, 219–226.
   PubMed Web of Science ®Google Scholar
• Draube, A., Pfister, R., Vockerodt, M., Schuster, S., Kube, D., Diehl, V. and Tesch, H. (2001) "Immunomagnetic enrich-ment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement", Ann. Hematol. 80, 83–89.
   PubMed Web of Science ®Google Scholar
• Bagg, A., Braziel, R.M., Arber, D.A., Bijwaard, K.E. and Chu, A.Y. (2002) "Immunoglobulin heavy chain gene analysis in lymphomas: a multi-center study demonstrating the heterogeneity of performance of polymerase chain reaction assays", J. Mol. Diagn. 4, 81–89.
   PubMed Web of Science ®Google Scholar
• Brisco, M.J., Tan, LW., Orsborn, AM. and Morley, A.A. (1990) "Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population", Br. J. Haematol. 75, 163–167.
   PubMed Web of Science ®Google Scholar
• Yamada, M., Hudson, S., Tournay, O., Bittenbender, S., Shane, S.S., Lange, B., Tsujimoto, Y, Caton, A.J. and Rovera, G. (1989) "Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-comple-mentarity-determining region (CDR-BI)-specific probes", Proc. Nat! Acad. Sci. USA 86, 5123–5127.
   PubMed Web of Science ®Google Scholar
• Deane, M., McCarthy, K.P., Wiedemann, L.M. and Norton, J.D. (1991) "An improved method for detection of B-lymphoid clonality by polymerase chain reaction", Leukemia 5, 726–730.
   PubMed Web of Science ®Google Scholar
• Owen, R.G., Johnson, R.J., Rawstron, A.C., Evans, P.A., Jack, A., Smith, G.M., Child, J.A. and Morgan, G.J. (1996) "Assessment of IgH PCR strategies in multiple myeloma", J. Clin. Pathol. 49, 672–675.
   PubMed Web of Science ®Google Scholar
• Aubin, J., Davi, E, Nguyen-Salomon, F., Leboeuf, D., Debert, C., Taher, M., Valensi, F., Canioni, D., Brousse, N. and Varet, B. (1995) "Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of donality in B cell malignancies", Leukemia 9, 471–479.
   PubMed Web of Science ®Google Scholar
• Diss, T.C., Peng, H., Wotherspoon, AC., Isaacson, P.G. and Pan, L. (1993) "Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type", J. Pathol. 169, 291–295.
   PubMed Web of Science ®Google Scholar
• Ramasamy, I., Brisco, M. and Morley, A. (1992) "Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms", J. Clin. Pathol. 45, 770–775.
   PubMed Web of Science ®Google Scholar
• Campbell, M.J., Zelenetz, AD., Levy, S. and Levy, R. (1992) "Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire", Mol. Immunol. 29, 193–203.
   PubMed Web of Science ®Google Scholar
• Gonzalez, D., Balanzategui, A., Garcia-Sanz, R., Gutierrez, N., Seabra, C., van Dongen, J.J., Gonzalez, M. and San Miguel, J.F. (2003) "Incomplete Dill-1 rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications", Leukemia 17, 1398–1403.
   PubMed Web of Science ®Google Scholar
• Billadeau, D., Blackstadt, M., Greipp, P., Kyle, R.A., Oken, M.M., Kay, N. and Van Ness, B. (1991) "Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease", Blood 78, 3021–3029.
   PubMed Web of Science ®Google Scholar
• Zhou, P., Zhang, Y., Martinez, C., Kalakonda, N., Nimer, S.D. and Comenzo, R.L. (2003) "Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination", Blood 102, 477–479.
   PubMed Web of Science ®Google Scholar
• Heid, C.A., Stevens, J., Livak, K.J. and Williams, P.M. (1996) "Real time quantitative PCR", Genome Res. 6, 986–994.
   PubMed Web of Science ®Google Scholar
• Wittwer, CT., Herrmann, M.G., Moss, A.A. and Rasmussen, R.P. (1997) "Continuous fluorescence moni-toring of rapid cycle DNA amplification", Biotechniques 22, 130–138.
   PubMed Web of Science ®Google Scholar
• Förster, V. Th. (1948) "Zwischenmolekulare Energie-wander-ung und Fluoreszenz", Ann. Phys. (Leipzig) 2, 55–75.
   Web of Science ®Google Scholar
• Voena, C., Locatelli, G., Castellino, C., Omede, P., Ladetto, M., Zappone, E., Milani, R., Perfetti, V, Boccadoro, M., Pileri, A., Lusso, P., Villa, C., Malnati, M. and Corradini, P. (2002) "Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system", Br. J. Haematol. 117, 642–645.
   PubMed Web of Science ®Google Scholar
• Gonzalez, D., Gonzalez, M., Alonso, M.E., Lopez-Perez, R., Balanzategui, A., Chinon, MC., Silva, M., Garcia-Sanz, R. and San Miguel, J.F. (2003) "Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR", Leukemia 17, 1051–1057.
   PubMed Web of Science ®Google Scholar
• van der Velden, V.H., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J. and van Dongen, J.J. (2003) "Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects", Leukemia 17, 1013–1034.
   PubMed Web of Science ®Google Scholar
• Eckert, C., Landt, O., Taube, T., Seeger, K., Beyermarm, B., Proba, J. and Henze, G. (2000) "Potential of LightCyder technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia", Leukemia 14, 316–323.
   PubMed Web of Science ®Google Scholar
• Nakao, M., Janssen, J.W., Flohr, T. and Bartram, C.R. (2000) "Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology", Cancer Res. 60, 3281–3289.
   PubMed Web of Science ®Google Scholar
• Li, A.H., Forestier, E., Rosenquist, R. and Roos, G. (2002) "Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye", Exp. Hematol. 30, 1170–1177.
   PubMed Web of Science ®Google Scholar
• Kwan, E., Norris, M.D., Zhu, L., Ferrara, D., Marshall, G.M. and Haber, M. (2000) "Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction", Br. J. Haematol. 109, 430–434.
   PubMed Web of Science ®Google Scholar
• Donovan, J.W., Ladetto, M., Zou, G., Neuberg, D., Poor, C., Bowers, D. and Gribben, J.G. (2000) "Immunoglobulin heavy-chain consensus probes for real-time PCR quantifi-cation of residual disease in acute lymphoblastic leukemia", Blood 95, 2651–2658.
   PubMed Web of Science ®Google Scholar
• Pfitzner, T., Engert, A., Wittor, H., Schinkothe, T., Oberhauser, E, Schulz, H., Diehl, V. and Barth, S. (2000) "A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia", Leukemia 14, 754–766.
   PubMed Web of Science ®Google Scholar
• Bruggemann, M., Droese, J., Bolz, I., Luth, P., Pott, C., von Neuhoff, N., Scheuering, U. and Kneba, M. (2000) "Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR", Leukemia 14, 1419–1425.
   PubMed Web of Science ®Google Scholar
• Verhagen, O.J., Willemse, M.J., Breunis, W.B., Wijkhuijs, A.J., Jacobs, D.C., Joosten, S.A., van Wering, ER., van Dongen, J.J. and van der Schoot, C.E. (2000) "Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia", Leukemia 14, 1426–1435.
   PubMed Web of Science ®Google Scholar
• Fenk, R., Kobbe, G., Arnold, C., Steidl, U., Huenerlitoerkoglu, A., Rohr, U.-E, Emde, T., Bernhard, A., Haas, R. and Kronenwett, R. (2003) "Quantification of minimal residual disease by real-time IgH-PCR using TaqMan chemistry together with LightCycler technology predicts relapse in multiple myeloma", Hematol. J. 4, S179 [abstract].
   Google Scholar
• Weidmann, M., Meyer-Konig, U. and Hufert, ET. (2003) "Rapid detection of herpes simplex virus and varicella-zoster virus infections by real-time PCR", J. Clin. Micro biol. 41, 1565–1568.
   PubMed Web of Science ®Google Scholar
• Mackay, I.M., Jacob, K.C., Woolhouse, D., Waller, K., Syrmis, MW., VVhiley, D.M., Siebert, D.J., Nissen, M. and Sloots, T.P. (2003) "Molecular assays for detection of human metapneumovirus", J. Clin. Micro biol. 41, 100–105.
   PubMed Web of Science ®Google Scholar
• Terry, C.F., Shanahan, D.J., Ballam, L.D., Harris, N., McDowell, D.G. and Parkes, H.C. (2002) "Real-time detection of genetically modified soya using Lightcycler and ABI 7700 platforms with TaqMan, Scorpion, and SYBR Green I chemistries", J. AOAC Int. 85, 938–944.
   PubMed Web of Science ®Google Scholar
• Watkins-Riedel, T., Woegerbauer, M., Hollemann, D. and Hufnagl, P. (2002) "Rapid diagnosis of enterovirus infections by real-time PCR on the LightCycler using the TaqMan format", Diagn. Microbiol. Infect. Dis. 42, 99–105.
   PubMed Web of Science ®Google Scholar
• Stordeur, P., Poulin, L.F., Craciun, L., Zhou, L., Schandene, L., de Lavareille, A., Goriely, S. and Goldman, M. (2002) "Cytokine mRNA quantification by real-time PCR", J. Immunol. Methods 259, 55–64.
   PubMed Web of Science ®Google Scholar
• Woo, T.H., Patel, B.K., Cinco, M., Smythe, L.D., Norris, MA., Symonds, M.L., Dohnt, M.F. and Piispanen, J. (1999) "Identification of Leptospira biflexa by real-time homo-geneous detection of rapid cycle PCR product", J. Micro biol. Methods 35, 23–30.
   PubMed Web of Science ®Google Scholar
• Kearns, AM., Guiver, M., James, V. and King, J. (2001) "Development and evaluation of a real-time quantitative PCR for the detection of human cytomegalovirus", J. Virol. Methods 95, 121–131.
   PubMed Web of Science ®Google Scholar
• Hein, I., Lehner, A., Rieck, P., Klein, K., Brandi, E. and Wagner, M. (2001) "Comparison of different approaches to quantify Staphylococcus aureus cells by real-time quantitative PCR and application of this technique for examination of cheese", App!. Environ. Microbiol. 67, 3122–3126.
   PubMed Web of Science ®Google Scholar
• McAvin, J.C., Reilly, P.A., Roudabush, R.M., Barnes, W.J., Salmen, A., Jackson, G.W., Beninga, K.K., Astorga, A., McCleskey, F.K., Huff, W.B., Niemeyer, D. and Lohman, K.L. (2001) "Sensitive and specific method for rapid identification of Streptococcus pneumoniae using real-time fluorescence PCR", J. Clin. Microbiol. 39, 3446–3451.
   PubMed Web of Science ®Google Scholar
• Kreuzer, K.A., Lass, U., Bohn, A., Landt, O. and Schmidt, C.A. (1999) "LightCycler technology for the quantitation of bcr/abl fusion transcripts", Cancer Res. 59, 3171–3174.
   PubMed Web of Science ®Google Scholar
• Corradini, P., Voena, C., Tarella, C., Astolfi, M., Ladetto, M., Palumbo, A., Van Lint, M.T., Bacigalupo, A., Santoro, A., Musso, M., Majolino, I., Boccadoro, M. and Pileri, A. (1999) "Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hemato-poietic cells", J. Clin. Oncol. 17, 208–215.
   PubMed Web of Science ®Google Scholar
• Corradini, P., Voena, C., Astolfi, M., Ladetto, M., Tarella, C., Boccadoro, M. and Pileri, A. (1995) "High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting", Blood 85, 1596–1602.
   PubMed Web of Science ®Google Scholar
• Martinelli, G., Terragna, C., Zamagni, E., Ronconi, S., Tosi, P., Lemoli, R.M., Bandini, G., Motta, M.R., Testoni, N., Amabile, M., Ottaviani, E., Vianelli, N., de Vivo, A., Gozzetti, A., Tura, S. and Cavo, M. (2000) "Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma", J. Clin. Oncol. 18, 2273–2281.
   PubMed Web of Science ®Google Scholar
• Bird, J.M., Bloxham, D., Samson, D., Marcus, R.E., Russell, N.H., Kelsey, S.M., Newland, A.C. and Apperley, J.F. (1994) "Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients", Br. J. Haematol. 88, 110–116.
   PubMed Web of Science ®Google Scholar
• Barbui, A.M., Galli, M., Dotti, G., Belli, N., Borleri, G., Gritti, G., Bellavita, P., Viero, P., Comotti, B., Barbui, T. and Rambaldi, A. (2002) "Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma", Br. J. Haematol. 116, 202–210.
   PubMed Web of Science ®Google Scholar
• Patriarca, F., Damiani, D., Fanin, R., Grimaz, S., Geromin, A., Cerno, M., Sperotto, A., Silvestri, F., Zaja, F. and Baccarani, M. (2000) "High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome", Haematologica 85, 269–274.
   PubMed Web of Science ®Google Scholar
• Dyson, P.C., Horvath, N., Joshua, D., Barrow, L., Van Holst, N.G., Brown, R., Gibson, J. and To, L.B. (2000) "CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma", Bone Marrow Transplant. 25, 1175–1184.
   PubMed Web of Science ®Google Scholar
• Vescio, R., Schiller, G., Stewart, A.K., Ballester, O., Noga, S., Rugo, H., Freytes, C., Stadtmauer, E., Tarantolo, S., Sahebi, F., Stiff, P., Meharchard, J., Schlossman, R., Brown, R., Tully, H., Benyunes, M., Jacobs, C., Berenson, R., DiPersio, J., Anderson, K. and Berenson, J. (1999) "Multicenter phase In trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma", Blood 93, 1858–1868.
   PubMed Web of Science ®Google Scholar
• Lemoli, R.M., Martinelli, G., Olivieri, A., Motta, M.R., Rizzi, S., Terragna, C., Leopardi, G., Benni, M., Ronconi, S., Canton, I., Rondelli, D., Mangianti, S., Leoni, P., Montanan, M., Cavo, M. and Tura, S. (1999) "Selection and transplanta-tion of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study", Br. J. Haematol. 107, 419–428.
   PubMed Web of Science ®Google Scholar
• Abonour, R., Scott, K.M., Kunkel, L.A., Robertson, M.J., Hromas, R., Graves, V, Lazaridis, E.N., Cripe, L., Gharpure, V, Traycoff, C.M., Mills, B., Srour, E.F. and Cornetta, K. (1998) "Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma", Bone Marrow Transplant. 22, 957–963.
   PubMed Web of Science ®Google Scholar
• Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Lee, M., Wu, C.H., Cao, J., Lee, J.C., Lichtenstein, A., Lill, M., Berenson, R. and Berenson, J. (1998) "Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma", Bone Marrow Transplant. 21, 141–145.
   PubMed Web of Science ®Google Scholar
• Anderson, K.C., Andersen, J., Soiffer, R., Freedman, AS., Rabinowe, S.N., Robertson, M.J., Spector, N., Blake, K., Murray, C. and Freeman, A. (1993) "Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma", Blood 82, 2568–2576.
   PubMed Web of Science ®Google Scholar
• Stewart, AK., Vescio, R., Schiller, G., Ballester, O., Noga, S., Rugo, H., Freytes, C., Stadtmauer, E., Tarantolo, S., Sahebi, F., Stiff, P., Meharchard, J., Schlossman, R., Brown, R., Tully, H., Benyunes, M., Jacobs, C., Berenson, R., White, M., DiPersio, J., Anderson, K.C. and Berenson, J. (2001) "Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial", J. Clin. Oncol. 19, 3771–3779.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Gazitt, Y, Leemhuis, T., Jagannath, S., Desikan, KR., Siegel, D., Fassas, A., Tindle, S., Nelson, J., Juttner, C., Tsukamoto, A., Hallagan, J., Atkinson, K., Reading, C., Hoffman, R. and Barlogie, B. (1998) "Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma", Blood 91, 4489–4495.
   PubMed Web of Science ®Google Scholar
• Lemoli, R.M., Cavo, M. and Fortuna, A. (1996) "Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma", J. Hematother. 5, 339–349.
   PubMedGoogle Scholar
• Johnson, R.J., Owen, R.G., Smith, G.M., Child, J.A., Galvin, M., Newton, L.J., Rawstron, A., Major, K., Woodhead, V, Robinson, F., Jack, A. and Morgan, G.J. (1996) "Peripheral blood stem cell transplantation in myeloma using CD34 selected cells", Bone Marrow Transplant. 17, 723–727.
   PubMed Web of Science ®Google Scholar
• Thunberg, U., Banghagen, M., Bengtsson, M., Christensen, L.D., Geisler, C.H., Gimsing, P., Lenhoff, S., Mortensen, B.T., Olofsson, T., Simonsson, B., Andersen, N.S., Sundstrom, C., Swedin, A., Sallstrom, J.F., Thuresson, B., Westin, J. and Carlson, K. (1999) "Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myeloma", Br. J. Haematol. 104, 546–552.
   PubMed Web of Science ®Google Scholar
• Cremer, F.W., Kiel, K., Sucker, C., Wacker, J., Atzberger, A., Haas, R., Goldschmidt, H. and Moos, M. (1997) "A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells", Leukemia 11, S41—S46.
   PubMed Web of Science ®Google Scholar
• Cremer, F.W., Kiel, K., Wallmeier, M., Haas, R., Goldschmidt, H. and Moos, M. (1998) "Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone", Exp. Hematol. 26, 969–975.
   PubMed Web of Science ®Google Scholar
• Ladetto, M., Omede, P., Sametti, S., Donovan, J.W., Astolfi, M., Drandi, D., Volpato, F., Giaccone, L., Giaretta, F., Palumbo, A., Bruno, B., Pileri, A., Gribben, J.G. and Boccadoro, M. (2002) "Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests", Exp. Hematol. 30, 529–536.
   PubMed Web of Science ®Google Scholar
• Kiel, K., Cremer, F.W., Ehrbrecht, E., Wallmeier, M., Hegenbart, U., Goldschmidt, H. and Moos, M. (1998) "First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield", Bone Marrow Transplant. 21, 1109–1115.
   PubMed Web of Science ®Google Scholar
• Lincz, L.F., Crooks, R.L., Way, S.L., Granter, N. and Spencer, A. (2001) "Tumour kinetics in multiple myeloma before, during, and after treatment", Leuk. Lymphoma 40, 373–384.
   PubMed Web of Science ®Google Scholar
• Lopez-Perez, R., Garcia-Sanz, R., Gonzalez, D., Balanzategui, A., Chillon, MC., Alaejos, I., Mateos, UV, Caballero, M.D., Corral, M., Orfao, A., Gonzalez, M. and San Miguel, J.F. (2001) "Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplan-tation", Bone Marrow Transplant. 28, 665–672.
   PubMed Web of Science ®Google Scholar
• Fermand, J.P., Alberti, C. and Marolleau, J.P. (2003) "Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma", Hematol. J. 4, S59, [abstract].
   Google Scholar
• Goldschmidt, H., Bouko, Y., Bourhid, J.H., Greinix, H.T., Salles, G., Derigs, G., Feremans, W., Hegenbart, U., Balckus, M., Samson, D., Garthon, G., Pico, J.L. and Apperley, J. (2000) "CD34+ selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: a randomised study from the EBMT", Blood 96, 558a [abstract].
   Web of Science ®Google Scholar
• Ramsey, D.J. and Schey, S.A. (2000) "Cytomegalovirus colitis after autologous transplantation for multiple myeloma", Br. J. Haematol. 110, 894–896.
   PubMed Web of Science ®Google Scholar
• Jacobson, J.L., Hussein, M.A., Barlogie, B., Dune, B.G. and Crowley, J.J. (2003) "A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience", Br. J. Haematol. 122, 441–450.
   PubMed Web of Science ®Google Scholar
• Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, R.A., Dewald, G.W., Van Ness, B., Van Wier, S.A., Henderson, K.J., Bailey, R.J. and Greipp, P.R. (2003) "Clinical and biologic implications of recurrent genomic aberrations in myeloma", Blood 101, 4569–4575.
   PubMed Web of Science ®Google Scholar
• Shaughnessy, J., Jacobson, J., Sawyer, J., McCoy, J., Fassas, A., Zhan, E, Bumm, K., Epstein, J., Anaissie, E., Jagannath, S., Vesole, D., Siegel, D., Desikan, R., Munshi, N., Badros, A., Tian, E., Zangari, M., Tricot, G., Crowley, J. and Barlogie, B. (2003) "Continuous absence of metaphase-defined cyto-genetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression", Blood 101, 3849–3856.
   PubMed Web of Science ®Google Scholar
• Rajkumar, S.V., Fonseca, R., Lacy, M.Q., Witzig, T.E., Lust, J.A., Greipp, P.R., Therneau, T.M., Kyle, R.A., Litzow, M.R. and Gertz, M.A. (1999) "Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell trans-plantation for myeloma", Bone Marrow Transplant. 23, 1261–1266.
   PubMed Web of Science ®Google Scholar
• Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Genevieve, E, Zandecki, M., Lai, J.L., Leleu, X., Jouet, J.P., Bauters, E, Harousseau, J.L., Bataille, R. and Mary, J.Y. (2001) "Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy", Blood 97, 1566–1571.
   PubMed Web of Science ®Google Scholar
• Tricot, G., Spencer, T., Sawyer, J., Spoon, D., Desikan, R., Fassas, A., Badros, A., Zangari, M., Munshi, N., Anaissie, E., Toor, A. and Barlogie, B. (2002) "Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants", Br. J. Haematol. 116, 211–217.
   PubMed Web of Science ®Google Scholar
• Majolino, I., Corradini, P., Scime, R., Falda, M., Bosi, A., Tarella, C., Musso, M., Olivieri, A., Boccadoro, M., Marceno, R., Santoro, A. and Pileri, A. (2003) "High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors", Bone Marrow Transplant. 31, 767–773.
   PubMed Web of Science ®Google Scholar
• Cavo, M., Terragna, C., Martinelli, G., Ronconi, S., Zamagni, E., Tosi, P., Lemoli, R.M., Benni, M., Pagliani, G., Bandini, G. and Tura, S. (2000) "Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma", Blood 96, 355–357.
   PubMed Web of Science ®Google Scholar
• Martinelli, G., Terragna, C., Zamagni, E., Ronconi, S., Tosi, P., Lemoli, R., Bandini, G., Testoni, N., Amabile, M., Ottaviani, E., Buonamici, S., Soverini, S., Montefusco, V., de Vivo, A., Bonifazi, E, Tura, S. and Cavo, M. (2000) "Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation", Haematologica 85, 930–934.
   PubMed Web of Science ®Google Scholar
• Corradini, P., Cavo, M., Lokhorst, H., Martinelli, G., Terragna, C., Majolino, I., Valagussa, P., Boccadoro, M., Samson, D., Bacigalupo, A., Russell, N., Montefusco, V, Voena, C. and Gahrton, G. (2003) "Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in multiple myeloma", Blood 102, 1927–1929.
   PubMed Web of Science ®Google Scholar
• Billadeau, D., Prosper, F., Verfaillie, C., Weisdorf, D. and Van Ness, B. (1997) "Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement", Leukemia 11, 1565–1570.
   PubMed Web of Science ®Google Scholar
• Lipinski, E., Cremer, F.W., Ho, A.D., Goldschmidt, H. and Moos, M. (2001) "Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peri-pheral blood stem cell transplantation", Bone Marrow Transplant. 28, 957–962.
   PubMed Web of Science ®Google Scholar
• Cremer, F.W., Ehrbrecht, E., Kiel, K., Benner, A., Hegenbart, U., Ho, A.D., Goldschmidt, H. and Moos, M. (2000) "Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma", Bone Marrow Transplant. 26, 851–858.
   PubMed Web of Science ®Google Scholar
• Rasmussen, T., Jensen, L., Honore, L. and Johnsen, H.E. (2000) "Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma", Blood 96, 4357–4359.
   PubMed Web of Science ®Google Scholar
• Richardson, PG., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, Kauffman, M., Adams, J., Schenkein, D.P. and Anderson, K.C. (2003) "A phase 2 study of bortezomib in relapsed, refractory myeloma", N. Engl. J. Med. 348, 2609–2617.
   PubMed Web of Science ®Google Scholar
• Richardson, PG., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, E, LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. and Anderson, K.C. (2002) "Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma", Blood 100, 3063–3067.
   PubMed Web of Science ®Google Scholar
• Barlogie, B., Shaughnessy, J., Zangari, M. and Tricot, G. (2002) "High-dose therapy and immunomodulatory drugs in multiple myeloma", Semin. Oncol. 29, 26–33.
   PubMed Web of Science ®Google Scholar
• Anderson, K.C. (2003) "Moving disease biology from the lab to the clinic", Cancer 97, 796–801.
   PubMed Web of Science ®Google Scholar
• Bergenbrant, S., Yi, Q., Osterborg, A., Bjorkholm, M., Osby, E., Mellstedt, H., Lefvert, A.K. and Holm, G. (1996) "Modulation of anti-idiotypic immune response by immu-nization with the autologous M-component protein in multiple myeloma patients", Br. J. Haematol. 92, 840–846.
   PubMed Web of Science ®Google Scholar
• Cabrera, R., Diaz-Espada, F., Barrios, Y., Briz, M., Fores, R., Barbolla, L., Sanjuan, I., Regidor, C., Penalver, F.J. and Fernandez, MN. (2000) "Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma", Bone Marrow Transplant. 25, 1105–1108.
   PubMed Web of Science ®Google Scholar
• Kwak, LW., Taub, D.D., Duffey, P.L., Bensinger, WI., Bryant, RM., Reynolds, C.W. and Longo, Di. (1995) "Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor", Lancet 345, 1016–1020.
   PubMed Web of Science ®Google Scholar
• Kwak, LW., Pennington, R. and Longo, D.L. (1996) "Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts", Blood 87, 3053–3060.
   PubMed Web of Science ®Google Scholar
• Li, Y, Bendandi, M., Deng, Y., Dunbar, C., Munshi, N., Jagannath, S., Kwak, LW. and Lyerly, H.K. (2000) "Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells", Blood 96, 2828–2833.
   PubMed Web of Science ®Google Scholar
• Lim, S.H. and Bailey-Wood, R. (1999) "Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma", Int. J. Cancer 83, 215–222.
   PubMed Web of Science ®Google Scholar
• Liso, A., Stockerl-Goldstein, K.E, Auffermann-Gretzinger, S., Benike, C.J., Reichardt, V, van Beckhoven, A., Rajapaksa, R., Engleman, E.G., Blume, K.G. and Levy, R. (2000) "Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma", Biol. Blood Marrow Transplant. 6, 621–627.
   PubMed Web of Science ®Google Scholar
• Massaia, M., Borrione, P., Battaglio, S., Mariam, S., Beggiato, E., Napoli, P, Voena, C., Bianchi, A., Coscia, M., Besostri, B., Peola, S., Stiefel, T., Even, J., Novero, D., Boccadoro, M. and Pileri, A. (1999) "Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy", Blood 94, 673–683.
   PubMed Web of Science ®Google Scholar
• Osterborg, A., Henriksson, L. and Mellstedt, H. (2000) "Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma", Acta Oncol. 39, 797–800.
   PubMed Web of Science ®Google Scholar
• Rasmussen, T., Hansson, L., Osterborg, A., Johnsen, H.E. and Mellstedt, H. (2003) "Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells", Blood 101, 4607–4610.
   PubMed Web of Science ®Google Scholar
• Reichardt, V.L., Okada, C.Y., Liso, A., Benike, C.J., Stockerl-Goldstein, K.E., Engleman, E.G., Blume, K.G. and Levy, R. (1999) "Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study", Blood 93, 2411–2419.
   PubMed Web of Science ®Google Scholar
• Titzer, S., Christensen, O., Manzke, O., Tesch, H., Wolf, J., Emmerich, B., Carsten, C., Diehl, V. and Bohlen, H. (2000) "Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects", Br. J. Haematol. 108, 805–816.
   PubMed Web of Science ®Google Scholar
• Wen, Y.J., Barlogie, B. and Yi, Q. (2001) "Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells", Blood 97, 1750–1755.
   PubMed Web of Science ®Google Scholar
• Yi, Q., Desikan, R., Barlogie, B. and Munshi, N. (2002) "Optimizing dendritic cell-based immunotherapy in mul-tiple myeloma", Br. J. Haematol. 117, 297–305.
   PubMed Web of Science ®Google Scholar
• Bakkus, M.H.C., Bouko, Y, Everaert, T., Lipinsky, E., Samson, D., Apperley, J.F., Thielemans, K., Van Camp, B., Benner, A., Goldschmidt, H., Moos, M. and Cremer, F.W. (2003) "Quantification of the post-transplantation tumor load in the bone marrow by PCR with allele-specific oligonucleotide primers is a prognostic parameter in multiple myeloma", Haematol. J. 4, S179 [abstract].
   Google Scholar
• Cooke, F., Bakkus, M., Thielemans, K., Pico, J.L., Apperley, J.F. and Samson, D. (1999) "Use of quantitative ASO-PCR to predict relapse in multiple myeloma", Br. J. Haematol. 105, 317–319.
   PubMed Web of Science ®Google Scholar
• Pongers-Willemse, M.J., Seriu, T., Stolz, F., d'Aniello, E., Gameiro, P., Pisa, P., Gonzalez, M., Bartram, C.R., Panzer-Grumayer, E.R, Biondi, A., San Miguel, J.F. and van Dongen, J.J. (1999) "Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia", Leukemia 13, 110–118.
   PubMed Web of Science ®Google Scholar